FIVE PRIME THERAPEUTICS INC Contracts & Agreements

119 Contracts & Agreements
Browse by Contract Category
Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Form of Gross-Up Agreement
FIVE PRIME THERAPEUTICS INC
2021
Agreement and Plan of Merger, dated as of March 4, 2021, by and among Amgen Inc., Franklin Acquisition Sub, Inc. and Five Prime Therapeutics, Inc
Merger Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
DE
2021
Underwriting Agreement, dated November 12, 2020, by and among the Company, Cowen and Company, LLC and SVB Leerink LLC
Underwriting Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
NY
2020
Sublease by and between the company and Sutro Biopharma, Inc., dated as of September 3, 2020
Lease Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
DE
2020
Offer Letter Agreement by and between the company and Thomas Civik, dated as of April 6, 2020
FIVE PRIME THERAPEUTICS INC
Biotechnology
2020
Amendment to Offer Letter Agreement by and between the company and William R. Ringo, dated as of April 16, 2020
FIVE PRIME THERAPEUTICS INC
Biotechnology
2020
Sales Agreement by and between the Company and Cowen and Company, LLC, dated as of August 6, 2020
Sales Agreements
FIVE PRIME THERAPEUTICS INC
2020
Letter Agreement by and between the company and William R. Ringo, dated as of March 6, 2020
FIVE PRIME THERAPEUTICS INC
2020
Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
FIVE PRIME THERAPEUTICS INC
Biotechnology
2020
Amendment to Offer Letter Agreement by and between the company and William R. Ringo, dated as of December 20, 2019
FIVE PRIME THERAPEUTICS INC
2020
Letter Agreement by and between the company and Francis Sarena, dated as of December 12, 2019
FIVE PRIME THERAPEUTICS INC
2020
Letter Agreement by and between the company and David V. Smith, dated as of December 12, 2019
FIVE PRIME THERAPEUTICS INC
Biotechnology
2020
Retention Letter Agreement by and between the company and David V. Smith, dated as of January 15, 2020
Retention Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2020
Retention Letter Agreement by and between the company and Helen Collins, dated as of January 15, 2020
Retention Agreements
FIVE PRIME THERAPEUTICS INC
2020
Retention Letter Agreement by and between the company and Francis Sarena, dated as of January 15, 2020
Retention Agreements
FIVE PRIME THERAPEUTICS INC
2020
Letter Agreement by and between the company and Helen Collins, dated as of December 12, 2019
FIVE PRIME THERAPEUTICS INC
2020
Executive Severance Benefit Plan and Summary Plan Description, effective November 20, 2019
Severance Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2020
Non-Employee Director Compensation Policy, effective November 21, 2019
Compensation Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2020
Amendment No. 3 to the Non-Exclusive License Agreement by and among the company, BioWa, Inc. and Lonza Sales AG, dated as of July 17, 2019
License Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2019
Amendment No. 4 to the Non-Exclusive License Agreement by and among the company, BioWa, Inc. and Lonza Sales AG, dated as of August 22, 2019
License Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2019
Separation Agreement by and between the company and Aron M. Knickerbocker, dated as of September 19, 2019
Separation Agreements
FIVE PRIME THERAPEUTICS INC
2019
Offer Letter Agreement by and between the company and William R. Ringo, dated as of October 4, 2019
FIVE PRIME THERAPEUTICS INC
Biotechnology
2019
Amendment to Offer Letter Agreement by and between the company and William R. Ringo, dated as of October 8, 2019
FIVE PRIME THERAPEUTICS INC
Biotechnology
2019
Consulting Agreement by and between the company and Lewis T. Williams, effective as of April 1, 2019
Consulting Agreements
FIVE PRIME THERAPEUTICS INC
2019
Offer Letter Agreement by and between the company and Bryan Irving, dated as of July 27, 2017
FIVE PRIME THERAPEUTICS INC
Biotechnology
2019
Offer Letter Agreement by and between the company and David V. Smith, dated as of October 24, 2018
FIVE PRIME THERAPEUTICS INC
2019
Executive Severance Benefits Agreement by and between the company and Bryan Irving, dated as of September 5, 2017
Severance Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2019
Executive Severance Benefits Agreement by and between the company and David V. Smith, dated as of November 26, 2018
Severance Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2019
Amendment No. 1 to the Confidential Consulting Agreement by and between the company and FLG Partners, LLC, dated as of October 13, 2018.v
Consulting Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2019
Amendment No. 1 to the Non-Exclusive License Agreement by and among the company, BioWa, Inc. and Lonza Sales AG, dated as of June 6, 2013
License Agreements
FIVE PRIME THERAPEUTICS INC
2019
Amendment No. 2 to the Non-Exclusive License Agreement by and among the company, BioWa, Inc. and Lonza Sales AG, dated as of April 27, 2018
License Agreements
FIVE PRIME THERAPEUTICS INC
2019
Amendment No. 1 to the License and Collaboration Agreement by and between the company and Zai Lab (Shanghai) Co., Ltd., dated as of December 21, 2018
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2019
Consulting Agreement by and between the company and Marc Belsky effective as of April 7, 2018
Consulting Agreements
FIVE PRIME THERAPEUTICS INC
2018
Amendment to Stock Option Agreements by and between the company and Marc Belsky, effective as of April 6, 2018
Stock Agreements
FIVE PRIME THERAPEUTICS INC
2018
Confidential Consulting Agreement, by and between the company and FLG Partners, LLC, effective as of April 13, 2018
Consulting Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2018
Offer Letter Agreement by and between the company and Lewis T. Williams, dated as of November 17, 2017
FIVE PRIME THERAPEUTICS INC
Biotechnology
2018
Offer Letter by and between the company and Helen Collins, dated as of May 12, 2016
FIVE PRIME THERAPEUTICS INC
2018
Executive Severance Benefits Agreement by and between the company and Helen Collins, dated as of March 20, 2017
Severance Agreements
FIVE PRIME THERAPEUTICS INC
2018
Annual Bonus Plan, effective January 1, 2018
Bonus & Incentive Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2018
Amendment No. 2 to the Exclusive License Agreement by and between the company and Galaxy Biotech, LLC, dated as of May 30, 2017
License Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2018
License and Collaboration Agreement, dated as of December 19, 2017, by and between the company and Zai Lab (Shanghai) Co., Ltd
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
2018
Underwriting Agreement, dated January 24, 2018, by and among Five Prime Therapeutics, Inc. and Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Leerink Partners LLC, as...
Underwriting Agreements
FIVE PRIME THERAPEUTICS INC
2018
Annual Bonus Plan
Bonus & Incentive Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2017
Offer Letter by and between the Company and Aron Knickerbocker, dated as of October 18, 2017
FIVE PRIME THERAPEUTICS INC
Biotechnology
2017
Amendment No. 2 to the Executive Severance Benefits Agreement by and between the Company and Aron Knickerbocker, dated as of October 18, 2017
Severance Agreements
FIVE PRIME THERAPEUTICS INC
2017
Amendment No. 1 to the 2013 Omnibus Incentive Plan
Bonus & Incentive Agreements
FIVE PRIME THERAPEUTICS INC
2017
Confidential Resignation Agreement and General Release of Claims by and between the Company and Robert Sikorski, dated as of April 30, 2017
Release Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2017
Five Prime Therapeutics, Inc. • Two Corporate Drive • South San Francisco, CA 94080 • Phone ###-###-#### • Fax ###-###-#### www.fiveprime.com
FIVE PRIME THERAPEUTICS INC
2017
Executive Severance Benefits Agreement
Severance Agreements
FIVE PRIME THERAPEUTICS INC
2017
Amendment No. 1 to the Executive Severance Benefits Agreement
Severance Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2017
Executive Severance Benefits Agreement
Severance Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2017
Five Prime Therapeutics, Inc. 2013 Omnibus Incentive Plan Restricted Stock Agreement
Bonus & Incentive Agreements
FIVE PRIME THERAPEUTICS INC
2017
LEASE THE COVE AT OYSTER POINT HCP OYSTER POINT III LLC, a Delaware limited liability company, as Landlord, and FIVE PRIME THERAPEUTICS, INC. a Delaware corporation, as Tenant....
Lease Agreements
FIVE PRIME THERAPEUTICS INC
2017
Amendment to the Exclusive License Agreement
License Agreements
FIVE PRIME THERAPEUTICS INC
2016
Executive Transition and Severance Benefits Agreement
Severance Agreements
FIVE PRIME THERAPEUTICS INC
2016
Amendment No. 2 to the Research Collaboration and License Agreement
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
NY
2016
Amendment No. 3 to the Respiratory Diseases Research Collaboration and License Agreement
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
DE
2016
Amendment No. 1 to the Research Collaboration and License Agreement
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
2016
Research Collaboration and License Agreement
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2015
Retention Award Agreement
Retention Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2015
CLINICAL TRIAL COLLABORATION AGREEMENT
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
DE
2015
3,410,000 Shares of Common Stock Five Prime Therapeutics, Inc. UNDERWRITING AGREEMENT
Underwriting Agreements
FIVE PRIME THERAPEUTICS INC
2015
FIRST AMENDMENT TO LEASE
Lease Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2014
Amendment No. 2 to the Respiratory Diseases Research Collaboration and License Agreement
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
DE
2014
Amendment No. 1 to the Research Collaboration and License Agreement
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
2014
Research Collaboration and License Agreement
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
2014
Stock Purchase Agreement
Stock Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
NY
2014
Shares of Common Stock Five Prime Therapeutics, Inc. UNDERWRITING AGREEMENT
Underwriting Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
NY
2014
Five Prime Therapeutics, Inc. 2013 Omnibus Incentive Plan Restricted Stock Agreement
Bonus & Incentive Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
DE
2014
Five Prime Therapeutics,Inc. · Two Corporate Drive · South San Francisco, CA 94080 · Phone ###-###-#### · Fax ###-###-#### www.fiveprime.com
FIVE PRIME THERAPEUTICS INC
Biotechnology
2014
EXECUTIVE SEVERANCE BENEFITS AGREEMENT
Severance Agreements
FIVE PRIME THERAPEUTICS INC
2014
EXECUTIVE SEVERANCE BENEFITS AGREEMENT
Severance Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2014
Amendment No. 1 to the Executive Severance Benefits Agreement
Severance Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2014
ANNEX SP SCHEDULE OF PAYMENTS TO NRC
FIVE PRIME THERAPEUTICS INC
Biotechnology
2013
Shares of Common Stock Five Prime Therapeutics, Inc. UNDERWRITING AGREEMENT
Underwriting Agreements
FIVE PRIME THERAPEUTICS INC
2013
Page 2 of8
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2013
AMENDMENT NO. 1 TO THE LICENSE AGREEMENT EFFECTIVE FEBRUARY 1, 2006 BETWEEN STANFORD UNIVERSITY AND FIVE PRIME THERAPEUTICS INC.
License Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2013
TECHNOLOGY LICENCE AGREEMENT
FIVE PRIME THERAPEUTICS INC
2013
INDEMNIFICATION AGREEMENT
Indemnification Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
DE
2013
Research Collaboration and License Agreement
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
2013
License andCollaboration Agreement by and between Five Prime Therapeutics, Inc. and Human Genome Sciences, Inc. LICENSE AND COLLABORATION AGREEMENT
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
2013
RESPIRATORY DISEASES RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between Glaxo Group Limited and Five Prime Therapeutics, Inc.
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
DE
2013
RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between GlaxoSmithKline LLC and Five Prime Therapeutics, Inc. RESEARCH COLLABORATION AND LICENSE AGREEMENT
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
2013
AMENDMENT No. 1 to the RESEARCH COLLABORATION AND LICENSE AGREEMENT (Muscle Diseases ResearchProgram Expansion)
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
2013
Exclusive License Agreement
License Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2013
EXCLUSIVE LICENSE AGREEMENT between THEREGENTS OF THE UNIVERSITY OF CALIFORNIA and FIVE PRIME THERAPEUTICS, INC. for RECEPTORS FOR FIBROBLAST GROWTH FACTORS UC Case No. *** TABLE...
License Agreements
FIVE PRIME THERAPEUTICS INC
2013
NON-EXCLUSIVE LICENSE AGREEMENT
License Agreements
FIVE PRIME THERAPEUTICS INC
2013
FIVE PRIME THERAPEUTICS, INC. 2013 EMPLOYEE STOCK PURCHASE PLAN
Stock Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2013
Five Prime Therapeutics, Inc. WARRANT TO PURCHASE SERIES A PREFERRED STOCK
Warrant Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2013
No. PAW 6 WARRANT TO PURCHASE 28,350 SHARES OF SERIES A PREFERRED STOCK
Warrant Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
DE
2013
Seventh Amended and Restated Investor Rights Agreement
Investor Rights Agreements
FIVE PRIME THERAPEUTICS INC
2013
FIVE PRIME THERAPEUTICS, INC. 2002 EQUITY INCENTIVE PLAN ADOPTED: MARCH 14, 2002 APPROVED BY STOCKHOLDERS: MARCH 14, 2002 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS ONMAY 21,...
Bonus & Incentive Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2013
FIVE PRIME THERAPEUTICS, INC. 2002 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT (INCENTIVE STOCK OPTION OR NONSTATUTORY STOCKOPTION)
Bonus & Incentive Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2013
FIVE PRIME THERAPEUTICS, INC. 2010 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:OCTOBER 28, 2010 APPROVED BY THESTOCKHOLDERS: DECEMBER 9, 2010 TERMINATION DATE:OCTOBER...
Bonus & Incentive Agreements
FIVE PRIME THERAPEUTICS INC
2013
Option Agreement (Incentive Stock Option or Nonstatutory Stock Option) Five Prime Therapeutics, Inc. 2010 Equity Incentive Plan
Bonus & Incentive Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2013
FIVE PRIME THERAPEUTICS, INC. 2013 OMNIBUS INCENTIVE PLAN TABLE OF CONTENTS
Bonus & Incentive Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
DE
2013
FIVE PRIME THERAPEUTICS, INC. 2013 OMNIBUS INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT
Bonus & Incentive Agreements
FIVE PRIME THERAPEUTICS INC
2013
FIVE PRIME THERAPEUTICS, INC. 2013 OMNIBUS INCENTIVE PLAN NON-QUALIFIED OPTION AGREEMENT
Bonus & Incentive Agreements
FIVE PRIME THERAPEUTICS INC
2013
Five Prime Therapeutics, Inc. 1650 Owens Street, Suite 200 San Francisco, CA 94158
FIVE PRIME THERAPEUTICS INC
Biotechnology
2013
Five Prime Therapeutics, Inc. Two Corporate Drive South San Francisco, CA 94080 Main: (415) 365-5600 Fax: (415) 520-9842
FIVE PRIME THERAPEUTICS INC
2013
2007 EXECUTIVE SEVERANCE BENEFITS AGREEMENT
Severance Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2013
EXECUTIVE SEVERANCE BENEFITS AGREEMENT
Severance Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2013
Amendment No. 1 to the Executive Severance BenefitsAgreement
Severance Agreements
FIVE PRIME THERAPEUTICS INC
2013
EXECUTIVE SEVERANCE BENEFITS AGREEMENT
Severance Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2013
Amendment No. 1 to the Executive Severance BenefitsAgreement
Severance Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2013
Indemnity Agreement
FIVE PRIME THERAPEUTICS INC
2013
Research Collaboration and License Agreement
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
2013
License andCollaboration Agreement by and between Five Prime Therapeutics, Inc. and Human Genome Sciences, Inc. LICENSE AND COLLABORATION AGREEMENT
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
2013
RESPIRATORY DISEASES RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between Glaxo Group Limited and Five Prime Therapeutics, Inc.
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
2013
Amendment No. 1 to the Respiratory Diseases Research Collaboration and License Agreement
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
DE
2013
RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between GlaxoSmithKline LLC and Five Prime Therapeutics, Inc. RESEARCH COLLABORATION AND LICENSE AGREEMENT
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
2013
AMENDMENT No. 1 to the RESEARCH COLLABORATION AND LICENSE AGREEMENT (Muscle Diseases ResearchProgram Expansion)
Collaboration Agreements
FIVE PRIME THERAPEUTICS INC
2013
Exclusive License Agreement
License Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2013
EXCLUSIVE LICENSE AGREEMENT between THEREGENTS OF THE UNIVERSITY OF CALIFORNIA and FIVE PRIME THERAPEUTICS, INC. for RECEPTORS FOR FIBROBLAST GROWTH FACTORS UC Case No. *** TABLE...
License Agreements
FIVE PRIME THERAPEUTICS INC
2013
Master Services Agreement
Services Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
CA
2013
LEASE
Lease Agreements
FIVE PRIME THERAPEUTICS INC
2013
SUBLEASE
Lease Agreements
FIVE PRIME THERAPEUTICS INC
2013
FIVE PRIME THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE (2002 EQUITY INCENTIVE PLAN)
Bonus & Incentive Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2013
Amendment to Stock Option
Stock Agreements
FIVE PRIME THERAPEUTICS INC
Biotechnology
2013